Intas Pharmaceuticals Limited is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat.
Background: Regulatory expectations for topical and nasal products differ across Gulf Cooperation Council (GCC) and Middle East–North Africa (MENA) markets. Clear understanding of dossier formats, stability, labeling and site requirements is essential for predictable approvals. Objectives: To compare prevailing frameworks and outline practical strategies that shorten review cycles while ensuring compliance for topical and nasal dosage forms. Methods: A structured desk review of primary guidance from GCC-DR, SFDA (Saudi Arabia), MOHAP (UAE), EDA (Egypt), and JFDA (Jordan), alongside WHO/ICH quality references, was synthesized into an actionable comparison. Results: GCC countries show higher alignment via centralized and national eCTD pathways, while MENA markets are heterogeneous in format and evidence expectations (e.g., device performance for nasal sprays). Conclusion: Regionaware sequencing, robust stability justifications (Zone IVB), and early alignment on country-specific documentation materially reduce risk of delay for topical and nasal submissions.
The present study outlines the preparation of lipid polymer hybrid nano-system, designed to deliver Crizotinib (CRZ), aiming to enhance its anticancer efficacy in lung cancer therapy. Self-assembled nanoprecipitation method was used for the preparation of hybrid nanoparticles. BBD (Box-Behnken Design) was employed to optimize the effects of polymer, lipid and surfactant concentration on particle size and entrapment efficiency. The optimized hybrid nanoparticles yielded particle size of 94.27 ± 3.15 nm and encapsulation efficiency of 81.13 ± 1.26
Therapeutic oligonucleotides (ONs), including antisense-oligonucleotides, small interfering RNA, aptamers, and conjugated modalities, have emerged as an important class of drugs with increasing clinical impact. Unlike small molecules, ONs undergo metabolism primarily through nuclease-mediated cleavage, generating complex profiles of shortened metabolites that often differ by a single nucleotide and may retain pharmacological or toxicological relevance. Comprehensive metabolite identification is therefore essential for understanding ONs pharmacokinetics (PK), tissue exposure, and safety. Liquid chromatography coupled to mass spectrometry (LC-MS) has become the principal analytical platform for ONs metabolite identification. Recent advances in chromatographic separation, high-resolution mass spectrometry, fragmentation strategies, and data processing tools have substantially improved the depth, confidence, and throughput of metabolite characterization. This review provides an overview of ONs biotransformation pathways and critically examines modern LC-MS strategies used for metabolite separation, detection, and structural elucidation. Emphasis is placed on high-resolution MS acquisition approaches, charge-state management, complementary fragmentation techniques, and software-assisted metabolite annotation. Emerging trends and future directions in ONs metabolite analysis are also discussed, with a focus on supporting translational PK and regulatory decision making.
Legacy sterile injectable products developed prior to the widespread adoption of Quality by Design (QbD) principles are often entered into the product life cycle with a limited quantitative understanding of process variability. The U.S. Food and Drug Administration's (FDA's) Process Validation Guidance (2011) recognizes Stage 3 continued process verification (CPV) as a life cycle activity and introduces heightened monitoring as a mechanism to establish a statistically meaningful baseline prior to routine monitoring. Industry has termed the two CPV sub-stages as Stage 3a and 3b. Published examples describing structured Stage 3a execution for commercial legacy injectables remain limited. This article presents a commercial-scale case study describing the design, execution, and outcomes of a Stage 3a monitoring program for a lyophilized injectable product. A risk based, statistically justified sampling strategy was implemented across multiple commercial batches to quantify intra and inter batch variability, evaluate spatial variability within the lyophilizer, and assess time-dependent degradation risks. Variance component analysis, regression analysis, and process capability metrics were applied to both historical and Stage 3a data. Results identified the total manufacturing time from active pharmaceutical ingredient (API) addition through filling as a parameter strongly correlated with impurity variability. The Stage 3a program enabled conversion of previously assumed controls into measurable and trended parameters and supported development of a data-driven Stage 3b monitoring strategy aligned with FDA and International Conference for Harmonisation (ICH) life cycle validation principles. This case study illustrates how Stage 3a can be effectively leveraged to close residual process knowledge gaps for legacy sterile injectable products.
Background: Data from developing countries on the utilization of guideline-directed medical therapy (GDMT) in the management of ST-segment elevation myocardial infarction (STEMI) remains limited. Suboptimal adherence to GDMT may contribute to poorer clinical outcomes in these settings. This study evaluated prescription patterns and adherence to GDMT in STEMI to inform rational drug use and improve quality of life. Methods: This prospective observational study analyzed prescription patterns during hospitalization and at discharge in consecutive STEMI patients across five centers in southern India. Demographics, comorbidities, laboratory parameters, echocardiographic findings, and reperfusion strategies were documented. The timing and utilization of GDMT were assessed with a 30 days postdischarge follow-up. Data were recorded in password-protected electronic software and analyzed. Results: Among 1020 patients, 967 were included in the final analysis, of whom 83.6% were male. Aspirin and statins were administered to 99.5% and 99.3% of patients, respectively. Clopidogrel was the most commonly used P2Y12 inhibitor (77.5%), while ticagrelor use increased from 20.6% on day 1 to 37.2% overall. Atorvastatin was the preferred statin (88.9%). At discharge, beta-blockers and renin–angiotensin–aldosterone system inhibitors were prescribed to 68% and 71% of patients, respectively, while ivabradine was used in 6.7%. In-hospital mortality rate was 3.7% ( n = 38). At the 30-day follow-up, adherence to prescribed therapy was good. Conclusion: This real-world study demonstrates high utilization of antiplatelets, statins, and beta-blockers, with atorvastatin as the statin of choice. Despite the availability of ticagrelor, clopidogrel remains the predominant P2Y12 inhibitor. While adherence to key GDMT components is encouraging, further optimization of comprehensive GDMT for STEMI patients remains warranted.
